StockNews.com Begins Coverage on Invitae (NYSE:NVTA)

StockNews.com assumed coverage on shares of Invitae (NYSE:NVTA) in a report issued on Sunday morning. The brokerage issued a hold rating on the medical research company’s stock.

Invitae Price Performance

The company’s 50 day moving average is $0.06 and its 200 day moving average is $0.40. Invitae has a 52-week low of $0.02 and a 52-week high of $0.02. The firm has a market capitalization of $1.07 million, a PE ratio of 0.00 and a beta of 1.59.

Institutional Trading of Invitae

Institutional investors and hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC bought a new position in shares of Invitae during the third quarter worth approximately $29,000. Longitude Cayman Ltd. increased its stake in shares of Invitae by 29.3% during the third quarter. Longitude Cayman Ltd. now owns 776,000 shares of the medical research company’s stock worth $470,000 after purchasing an additional 176,000 shares during the period. ARK Investment Management LLC increased its stake in shares of Invitae by 2.1% during the third quarter. ARK Investment Management LLC now owns 32,942,606 shares of the medical research company’s stock worth $19,937,000 after purchasing an additional 679,672 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Invitae by 4.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,652,650 shares of the medical research company’s stock worth $1,000,000 after acquiring an additional 64,228 shares during the period. Finally, Harbor Capital Advisors Inc. increased its stake in Invitae by 24.1% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 224,642 shares of the medical research company’s stock worth $136,000 after acquiring an additional 43,642 shares during the period. Institutional investors own 61.28% of the company’s stock.

Invitae Company Profile

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services.